INTRODUCTION {#s1}
============

Eastern Asia has the highest incidence of liver cancer in the world \[[@R1]\]. Hepatitis B virus (HBV) infection has a high prevalence (\> 5%) in the Chinese population \[[@R2], [@R3]\], and in 2012, more than half of new cases of liver cancer and death from the disease occurred in China \[[@R1]\]. Liver cancer is the third leading cause of cancer-related death in China \[[@R4]\], with an age-standardized 5-year relative survival rate of 10.1% \[[@R5]\]. Most of these are cases of hepatocellular carcinoma(HCC) \[[@R6]\]. In Guangxi province, which has a higher prevalence of HBV infection, aflatoxin B1 (AFB1) exposure levels and *tumor protein p53* (*TP53*) codon 249 mutation rates are higher than in other provinces, and are accompanied by higher mortality and morbidity from HCC \[[@R7]--[@R11]\]. Alcohol abuse, AFB1 exposure, HBV and hepatitis C virus infection are the major environmental factors associated with HCC \[[@R12], [@R13]\], while *TP53* mutation has been linked to HCC development and prognosis \[[@R14]--[@R17]\]. Thus, the population in Guangxi is suitable for exploring the relationship between AFB1 exposure, HBV infection, *TP53* codon 249 mutation, and HCC.

Alpha-fetoprotein (AFP) is a HCC biomarker that has been used to screen high-risk populations as well as for diagnosis, prognosis, and predicting recurrence. However, recent studies have shown that serum AFP levels lack diagnostic and/or prognostic specificity and sensitivity for HCC \[[@R18], [@R19]\]. As such, HCC guidelines of European Association for the Study of the Liver \[[@R20]\] and the American Association for the Study of Liver Diseases \[[@R21]\] no longer recommend serum AFP measurement; however, a recent clinical study in China suggested that it is still a valuable biomarker for HBV-related HCC \[[@R22]\]. It was also shown that HBVx protein can induce AFP expression in liver cells \[[@R23]--[@R25]\]. These findings suggest that AFP is closely associated with HBV and still valuable in HBV-related HCC. Given the high prevalence of HBV infection in China, serum AFP remains the most highly recommended biomarker for HCC diagnosis and prognosis according to Chinese HCC guidelines \[[@R26]\].

*Phospholipase C epsilon* (*PLCE*) *1* single nucleotide polymorphisms (SNPs) rs2274223 and rs3765524 have been identified in many cancer risk studies \[[@R27]\] and genome-wide association studies (GWAS) \[[@R28]\]. Rs2274223 A\>G has been linked to altered *PLCE1* expression in esophageal squamous cell carcinoma(ESCC) \[[@R29]--[@R31]\], and the G allele may contribute to increased cancer incidence \[[@R30]\]. Our previous GWAS of Chinese HBV-related HCC patients in Guangxi revealed that *PLCE1* gene polymorphism was associated with HBV-related HCC \[[@R32]\]. In our current study, we investigated the utility of *PLCE1* gene polymorphisms and expression in combination with serum AFP levels for predicting the prognosis of HBV-related HCC.

RESULTS {#s2}
=======

Patient characteristics and clinical outcomes {#s2_1}
---------------------------------------------

Patients were followed up after surgery until death or the final follow-up, which was in September 2014. A total of 421 HBV-related HCC patients completed the follow-up period successfully, with a lost to follow-up rate of 6.4%. The duration of follow up ranged from 12 to 117 months and the median survival time was 51 months. At the time of analysis, 188 (44.7%) of the patients had died. Clinical characteristics of patients and their association with overall survival (OS)are summarized in Table [1](#T1){ref-type="table"}. The Kaplan-Meier analysis revealed that tumor size and number, Barcelona Clinic Liver Cancer (BCLC) stage, and portal vein tumor thrombus (PVTT) were significantly associated with OS (log-rank test, *P* \< 0.001)and increased risk of death. In 364 patients (86.4%), a Child--Pugh score of A was related to OS (log-rank test, *P*=0.006). In 240 patients (57%), radical resection was related to OS (log-rank test, *P*=0.033). In 150 patients (35.6%), antiviral therapy after hepatectomy was associated with OS (log-rank test, *P*=0.004) as compared to those who did not receive the therapy. Other clinical characteristics were not associated with OS.

###### Clinical characteristics of HBV-related HCC patients

  Variables                          Patients(n=421)   No. of events (%)   MST(months)   HR (95% CI)           Log-rank P
  ---------------------------------- ----------------- ------------------- ------------- --------------------- ------------
  **Age (years)**                                                                                              0.186
   **≤60**                           367               162 (44.1)          58            1                     
   **\>60**                          54                25 (46.3)           39            1.326 (0.869-2.025)   
  **Gender**                                                                                                   0.274
   **Male**                          371               169 (45.6)          51            1                     
   **Female**                        50                18 (36.0)           51            0.764 (0.470-1.243)   
  **Ethnicity**                                                                                                0.978
   **Han**                           259               117 (45.2)          51            1                     
   **Minority**                      162               70 (43.2)           51            1.004 (0.746-1.353)   
  **BMI**                                                                                                      0.683
   **≤25**                           332               145 (43.7)          51            1                     
   **\>25**                          89                42 (47.2)           51            0.931 (0.659-1.315)   
  **Smoking status**                                                                                           0.124
   **None**                          272               115 (42.3)          61            1                     
   **Ever**                          149               72 (48.3)           40            1.259 (0.937-1.692)   
  **Drinking status**                                                                                          0.608
   **None**                          255               109 (42.7)          51            1                     
   **Ever**                          166               78 (47.0)           45            1.079 (0.806-1.443)   
  **Child--Pugh score**                                                                                        0.006
   **A**                             364               157 (43.1)          58            1                     
   **B**                             57                30 (52.6)           34            1.718 (1.161-2.542)   
  **Cirrhosis**                                                                                                0.225
   **No**                            47                18 (38.3)           88            1                     
   **Yes**                           374               169 (45.2)          51            1.348 (0.829-2.193)   
  **Radical resection&**                                                                                       0.033
   **Yes**                           240               96 (40.0)           73            1                     
   **None**                          171               86 (50.3)           40            1.368 (1.023-1.831)   
  **Portal hypertension†**                                                                                     0.595
   **No**                            217               103 (47.5)          57            1                     
   **Yes**                           181               77 (42.5)           45            1.084 (0.804-1.462)   
  **Pathological diagnosis‡**                                                                                  0.974
   **Well differentiated**           23                10 (43.5)           47            1                     
   **Moderately differentiated**     323               143 (44.3)          51            1.074 (0.565-2.040)   
   **Poorly differentiated**         12                5 (41.7)            40            1.034 (0.353-3.027)   
  **Adjuvant antiviral treatment**                                                       0.004                 
   **No**                            271               146 (53.9)          41            1                     
   **Yes**                           150               41 (27.3)           NA            0.605 (0.426-0.858)   
  **Tumor behavior**                                                                                           
  **Tumor size (cm)**                                                                                          \<0.001
   **\<10**                          316               126 (39.9)          71            1                     
   **≥10**                           105               61 (58.1)           34            1.925 (1.414-2.621)   
  **Tumor number**                                                                                             \<0.001
   **Single**                        309               120 (38.8)          61            1                     
   **Multiple**                      112               67 (59.8)           28            1.891 (1.401-2.551)   
  **Regional invasion**                                                                                        0.068
   **Absence**                       358               158 (44.1)          58            1                     
   **Presence**                      63                29 (46.0)           40            1.445 (0.968-2.156)   
  **BCLC stage**                                                                                               \<0.001
   **A**                             250               81 (32.4)           95            1                     
   **B**                             69                40 (58.0)           39            2.115 (1.447-3.091)   
   **C**                             102               66 (64.7)           25            3.216 (2.312-4.473)   
  **PVTT**                                                                                                     \<0.001
   **No**                            352               138 (39.2)          71            1                     
   **Yes**                           69                49 (71.0)           19            2.970 (2.135-4.131)   

Notes: & Information of radical resection was unavailable in 10 patients; † Information of portal hypertension was unavailable in 23 patients; ‡ Information of pathological diagnosis was unavailable in 63 patients; BMI, body mass index; BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus; MST, median survival time; HR, hazard ratio; CI, confidence interval.

Bioinformatics analysis {#s2_2}
-----------------------

The success rate for genotyping both SNPs was 100% ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"} and [2](#SD1){ref-type="supplementary-material"}). The genotype frequencies of rs2274223 and rs3765524 were consistent with Hardy-Weinberg equilibrium(χ^2^=3.091, *P*=0.079). A haplotype analysis of the two selected SNPs in HBV-related HCC patients and the normal Chinese Han in Beijing (CHB) population revealed a haplotype block (block pairwise r^2^=1.0 for normal CHB population; block pairwise r^2^=1.0, A~rs2274223~C~rs3765524~=75.7% and G~rs2274223~T~rs3765524~=24.3% for HBV-related HCC patients) (Figure [1A, 1B](#F1){ref-type="fig"}). Both SNPs were non-synonymous (rs2274223: H1927R; rs3765524: T1777I) and located in exons; rs2274223 was a Tag SNP of *PLCE1*. In addition, both SNPs were predicted to be 'Benign' and 'Tolerated' by PolyPzhen-2 (<http://genetics.bwh.harvard.edu/pph2/index.shtml>) and SIFT (<http://sift.jcvi.org/>) computational tools.

![Patterns of LD plots for two selected SNPs in the *PLCE1* gene\
**(A)** Pattern of LD plot and pairwise LD (r^2^) value calculated based on HapMap data of CHB samples. **(B)** Pattern of LD plot and pairwise LD (r^2^) value calculated based on data from the current study of HBV-related HCC cases.](oncotarget-08-29202-g001){#F1}

Analysis of genetic polymorphisms and haplotypes for different serum AFP levels {#s2_3}
-------------------------------------------------------------------------------

The genotype distributions of rs2274223 and rs3765524 for different serum AFP levels are shown in Table [2](#T2){ref-type="table"}. In the codominant genetic model, after adjusting for the Child--Pugh score, radical resection, antiviral therapy after hepatectomy, tumor size, tumor number, BCLC stage, PVTT, and regional invasion, single-locus analyses revealed that genotype GG of *PLCE1* rs2274223 was associated with an increased risk for AFP cut-off levels of 200 and 400 ng/ml in HBV-related HCC (GG vs. AA; adjusted *P*=0.013, adjusted odds ratio \[OR\]=3.014, 95% confidence interval \[CI\]=1.258--7.224 for an AFP cut-off level of 200 ng/ml; and adjusted *P*=0.020, adjusted OR=2.686, 95% CI=1.169--6.173 for an AFP cut-off level of 400 ng/ml) as compared to genotype AA. In the dominant genetic model of rs2274223, G (AG/GG) allele carriers also showed increased risk in HBV-related HCC with AFP cut-off levels of 200 and 400 ng/ml (AG/GG vs. AA; adjusted *P*=0.024, adjusted OR= 1.607, 95% CI= 1.065--2.424 for an AFP cut-off level of 200 ng/ml; and adjusted *P*= 0.028, adjusted OR= 1.588, 95% CI= 1.052--2.399 for an AFP cut-off level of 400 ng/ml) as compared to AA carriers. The results for rs3765524 were the same as for rs2274223; that is, the T (CT/TT) allele was associated with an increased risk for AFP cut-off levels of 200 and 400 ng/ml as compared to CC. In the haplotype analysis, the GT haplotype was associated with an increased risk for AFP cut-off levels of 200 and 400 ng/ml in HBV-related HCC (GT vs. AC; adjusted P=0.004, adjusted OR= 1.629, 95% CI= 1.164--2.281 for an AFP cut-off level of 200 ng/ml; and adjusted P= 0.006, adjusted OR= 1.592, 95% CI= 1.140--2.224 for an AFP cut-off level of 400 ng/ml). Both rs2274223 and rs3765524 genotype distributions and haplotype analysis results were non-significant for an AFP cut-off level of 20 ng/ml.

###### Genotype and haplotype distributions of PLCE1 at different serum AFP levels in HBV-related HCC patients

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables        AFP (ng/ml)   Crude OR\   Crude P              Adjusted OR (95%CI)   Adjusted P§          AFP (ng/ml)   Crude OR\   Crude P   Adjusted OR (95%CI)   Adjusted P§   AFP (ng/ml)          Crude OR\   Crude P   Adjusted OR (95%CI)   Adjusted P§                                       
                                 (95%CI)                                                                                   (95%CI)                                                                        (95%CI)                                                                                       
  ---------------- ------------- ----------- -------------------- --------------------- -------------------- ------------- ----------- --------- --------------------- ------------- -------------------- ----------- --------- --------------------- -------------------- ------- -------------------- -------
  **Genotypes**                                                                                                                                                                                                                                                                                         

  **rs2274223**                                                                                                                                                                                                                                                                                         

   **AA**          78            177         1                                          1                                  138         117       1                                   1                                152       103                   1                            1                    

   **AG**          35            102         1.284(0.805-2.049)   0.294                 1.357(0.833-2.210)   0.22          63          74        1.385(0.913-2.101)    0.125         1.424(0.922-2.198)   0.111       70        67                    1.412(0.930-2.146)   0.105   1.427(0.922-2.209)   0.111

   **GG**          6             23          1.689(0.662-4.312)   0.273                 1.672(0.634-4.408)   0.298         8           21        3.096(1.322-7.249)    0.009         3.014(1.258-7.224)   0.013       10        19                    2.804(1.253-6.275)   0.012   2.686(1.169-6.173)   0.02

   **AG+GG**       41            125         1.344(0.864-2.090)   0.190                 1.403(0.884-2.228)   0.15          71          95        1.578(1.064-2.340)    0.023         1.607(1.065-2.424)   0.024       80        86                    1.586(1.070-2.353)   0.022   1.588(1.052-2.399)   0.028

  **rs3765524**                                                                                                                                                                                                                                                                                         

   **CC**          78            177         1                                          1                                  138         117       1                                   1                                152       103                   1                            1                    

   **CT**          35            102         1.284(0.805-2.049)   0.294                 1.357(0.833-2.210)   0.22          63          74        1.385(0.913-2.101)    0.125         1.424(0.922-2.198)   0.111       70        67                    1.412(0.930-2.146)   0.105   1.427(0.922-2.209)   0.111

   **TT**          6             23          1.689(0.662-4.312)   0.273                 1.672(0.634-4.408)   0.298         8           21        3.096(1.322-7.249)    0.009         3.014(1.258-7.224)   0.013       10        19                    2.804(1.253-6.275)   0.012   2.686(1.169-6.173)   0.02

   **CT+TT**       41            125         1.344(0.864-2.090)   0.190                 1.403(0.884-2.228)   0.15          71          95        1.578(1.064-2.340)    0.023         1.607(1.065-2.424)   0.024       80        86                    1.586(1.070-2.353)   0.022   1.588(1.052-2.399)   0.028

  **Haplotypes**                                                                                                                                                                                                                                                                                        

   **AC**          191           456         1                                          1                                  339         308       1                                   1                                374       273                   1                            1                    

   **GT**          47            148         1.319(0.912-1.908)   0.142                 1.352(0.922-1.983)   0.123         79          116       1.616(1.168-2.237)    0.004         1.629(1.164-2.281)   0.004       90        105                   1.598(1.158-2.205)   0.004   1.592(1.140-2.224)   0.006
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Notes: § Adjustment for Child--Pugh score, tumor size, tumor number, BCLC stage, radical resection, regional invasion, adjuvant antiviral treatment, PVTT in logistic regression model; OR, odds ratio; CI, confidence interval.

Association between haplotypes and clinical features {#s2_4}
----------------------------------------------------

The association between *PLCE1* haplotypes and clinicopathological characteristics are shown in Table [3](#T3){ref-type="table"}. With the exception of Child--Pugh score, none of the associations between risk factors and *PLCE1* haplotypes reached statistical significance. A Child--Pugh score of B was significantly associated with haplotypes AC and GT, suggesting that the haplotype distribution of *PLCE1* differed according to liver functional reserve status in HBV-related HCC patients.

###### Association between risk factors and PLCE1 haplotypes in HBV-related HCC patients

  Variables                        AC(2n=842)   GT(2n=842)   OR (95%CI)            P
  -------------------------------- ------------ ------------ --------------------- -------
  **Tumor size(cm)**                                                               
   **≤10**                         494          138          1                     
   **≥10**                         153          57           1.334 (0.932-1.908)   0.115
  **Tumor number**                                                                 
   **Single**                      471          147          1                     
   **Multiple**                    176          48           0.874 (0.604-1.264)   0.474
  **Child--Pugh score**                                                            
   **A**                           548          180          1                     
   **B**                           99           15           0.461 (0.261-0.814)   0.008
  **BCLC stage**                                                                   
   **A**                           380          120          1                     
   **B**                           112          26           0.735 (0.458-1.180)   0.203
   **C**                           155          49           1.001 (0.684-1.466)   0.996
  **Radical resection&**                                                           
   **Yes**                         365          115          1                     
   **None**                        264          78           0.938 (0.675-1.302)   0.701
  **Regional invasion**                                                            
   **Absence**                     557          159          1                     
   **Presence**                    90           36           1.401 (0.916-2.143)   0.12
  **PVTT**                                                                         
   **No**                          542          162          1                     
   **Yes**                         105          33           1.051(0.685-1.614)    0.818
  **Pathological diagnosis‡**                                                      
   **Well differentiated**         31           15           1                     
   **Moderately differentiated**   502          144          0.593 (0.311-1.128)   0.111
   **Poorly differentiated**       19           5            0.544 (0.170-1.739)   0.304

Notes: & Information of radical resection was unavailable in 10 patients; ‡ Information of pathological diagnosis was unavailable in 63 patients; OR, odds ratio; CI, confidence interval; BCLC, Barcelona Clinic Liver Cancer stage; PVTT, portal vein tumor thrombus.

Relationship between haplotype and clinical outcome {#s2_5}
---------------------------------------------------

Results of the stratified analysis between *PLCE1* haplotypes and OS in HBV-related HCC patients are shown in Figure [2](#F2){ref-type="fig"}. All variables were stratified according to favorable and adverse clinicopathological characteristics. We found that *PLCE1* haplotypes were not associated with OS according to this stratification.

![Stratified analysis of association between *PLCE1* haplotype and OS in HBV-related HCC patients\
Variables were stratified according to favorable and adverse strata.](oncotarget-08-29202-g002){#F2}

The univariate analysis of *PLCE1* haplotypes revealed that patients with the GT haplotype had a shorter median survival time (MST) relative to those with the AC haplotype (42 vs. 57 months; log-rank *P*=0.445) (Table [4](#T4){ref-type="table"} and Figure [3A](#F3){ref-type="fig"}). After adjusting for risk factors in the Cox proportional hazards regression analysis, the MST was comparable between patients with different haplotypes and serum AFP levels. These results indicate that the prognosis of HBV-related HCC patients did not differ significantly between groups. In addition, based on AFP cut-off levels of 20, 200, and 400 ng/ml, lower AFP level was associated with longer MST as compared to higher AFP level (71 vs. 41 months for an AFP cut-off level of 20 ng/ml; 58 vs. 43 months for an AFP cut-off level of 200 ng/ml; and 58 vs. 43 months for an AFP cut-off level of 400 ng/ml) (Table [4](#T4){ref-type="table"}), although the difference was not statistically significant.

###### Survival analysis of HBV-related HCC patients according to PLCE1 haplotype and serum AFP level

  Variables            Patients (n=421)   No. of events (%)   MST (months)   Crude HR(95% CI)      Crude P   Adjusted HR(95% CI)   Adjusted P§
  -------------------- ------------------ ------------------- -------------- --------------------- --------- --------------------- -------------
  **Haplotypes ψ**                                                                                                                 
   **AC**              647                283 (46.9)          57             1                               1                     
   **GT**              195                91 (49.5)           42             1.096 (0.865-1.388)   0.449     1.143 (0.900-1.452)   0.272
  **AFP (ng/mL)**                                                                                                                  
  **Cut-off in 20**                                                                                                                
   **\<20**            119                40 (33.6)           71             1                               1                     
   **≥20**             302                147 (48.7)          41             1.683 (1.186-2.388)   0.004     1.276 (0.887-1.836)   0.19
  **Cut-off in 200**                                                                                                               
   **\<200**           209                86 (41.1)           58             1                               1                     
   **≥200**            212                101 (47.6)          43             1.238 (0.928-1.652)   0.146     0.938 (0.692-1.272)   0.682
  **Cut-off in 400**                                                                                                               
   **\<400**           232                96 (41.4)           58             1                               1                     
   **≥400**            189                91 (48.1)           43             1.262 (0.947-1.683)   0.112     0.985 (0.727-1.335)   0.923

Notes: ψ The number of heplotypes was 2n (2n=842); § Adjustment for Child--Pugh score, tumor size, tumor number, BCLC stage, radical resection, regional invasion, adjuvant antiviral treatment, PVTT in Cox proportional hazards regression model; MST, median survival time; HR, hazard ratio; CI, confidence interval.

![Survival curves of patients with different *PLCE1* haplotypes and joint-effects analysis of different AFP levels\
**(A)** OS stratified by AC and GT haplotypes. **(B--D)** OS stratified by joint-effects analysis of PLCE1 haplotypes and an AFP cut-off level of 20 ng/ml **(B)**, 200 ng/ml **(C)**, and 400 ng/ml **(D)**.](oncotarget-08-29202-g003){#F3}

Joint-effects analysis {#s2_6}
----------------------

We further analyzed the association between serum AFP level, *PLCE1* haplotypes, and HBV-related HCC patient survival outcomes. Based on AFP cut-off levels of 200 and 400 ng/ml, lower AFP level with the AC haplotype was associated with a longer MST (Table [5](#T5){ref-type="table"} and Figure [3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}) as compared to other patients. After adjusting for Child--Pugh score, radical resection, antiviral therapy after hepatectomy, tumor size and number, BCLC stage, PVTT, and regional invasion in the Cox proportional hazards regression model, the MST was similar among patients with different AFP levels and haplotypes. For the AFP cut-off level of 20 ng/ml, the MST of *PLCE1* haplotypes combined with AFP level differed significantly. The AC haplotype with AFP \< 20 ng/ml had a longer MST (75 vs. 41,71, and 40; log-rank test, *P*=0.0003) (Figure [3B](#F3){ref-type="fig"}); after adjusting for the above variables, the GT haplotype with AFP \< 20 ng/ml was associated with increased risk of death as compared to the AC haplotype (adjusted *P*=0.092, adjusted hazard ratio \[HR\]=1.539, 95% CI =0.932--2.541) (Table [5](#T5){ref-type="table"}). AC and GT haplotypes with AFP ≥ 20 ng/ml had significantly higher risk of death as compared to the AC haplotype with AFP \< 20 ng/ml (adjusted HR = 1.392, 95%CI= 1.034--1.873, and adjusted *P* = 0.029 for AC haplotype with AFP ≥ 20 ng/ml; and adjusted HR = 1.445, 95%CI= 1.015--2.057, and adjusted *P* = 0.041 for GT haplotype with AFP ≥ 20 ng/ml) (Table [5](#T5){ref-type="table"}).

###### Joint-effects survival analysis of PLCE1 haplotypes and serum AFP levels in HBV-related HCC patients

  Group     Haplotypes   AFP (ng/mL)     Patients (2n=842)   No. of events (%)   MST (months)   Crude HR(95% CI)      CrudeP    Adjusted HR(95% CI)   Adjusted P§
  --------- ------------ --------------- ------------------- ------------------- -------------- --------------------- --------- --------------------- -------------
  **I**     **AC**       **AFP \<20**    191                 59 (30.9)           75             1                               1                     
  **II**    **AC**       **AFP ≥20**     456                 224 (49.1)          41             1.826 (1.370-2.433)   0.00004   1.392 (1.034-1.873)   0.029
  **III**   **GT**       **AFP \<20**    47                  21 (44.7)           71             1.417 (0.861-2.332)   0.170     1.539 (0.932-2.541)   0.092
  **IV**    **GT**       **AFP ≥20**     148                 70 (47.3)           40             1.817 (1.285-2.571)   0.001     1.445 (1.015-2.057)   0.041
  **A**     **AC**       **AFP \<200**   339                 136 (40.1)          61             1                               1                     
  **B**     **AC**       **AFP ≥200**    308                 147 (47.7)          51             1.256 (0.994-1.586)   0.056     0.961 (0.751-1.229)   0.749
  **C**     **GT**       **AFP \<200**   79                  36 (45.6)           51             1.124 (0.779-1.624)   0.532     1.282 (0.885-1.858)   0.189
  **D**     **GT**       **AFP ≥200**    116                 55 (47.4)           40             1.301 (0.951-1.780)   0.100     1.034 (0.750-1.424)   0.839
  **1**     **AC**       **AFP \<400**   374                 150 (40.1)          61             1                               1                     
  **2**     **AC**       **AFP ≥400**    273                 133 (48.7)          50             1.286 (1.017-1.624)   0.035     1.007 (0.786-1.290)   0.956
  **3**     **GT**       **AFP \<400**   90                  42 (46.7)           51             1.128 (0.801-1.588)   0.492     1.240 (0.876-1.754)   0.225
  **4**     **GT**       **AFP ≥400**    105                 49 (46.7)           36             1.318 (0.954-1.821)   0.094     1.077 (0.775-1.499)   0.658

Notes: § Adjustment for Child--Pugh score, tumor size, tumor number, BCLC stage, radical resection, regional invasion, adjuvant antiviral treatment, PVTT in Cox proportional hazards regression model; MST, median survival time; HR, hazard ratio; CI, confidence interval.

Gene expression omnibus (GEO)data analysis {#s2_7}
------------------------------------------

A total of 218 HCC patients from GSE14520 \[[@R33]\] with a history of HBV infection or HBV-related liver cirrhosis were recruited for further analysis. The mRNA expression of *PLCE1*and *AFP* (Affymetrix Probe Set IDs: 205112_at and 204694_at, respectively) differed between HCC and adjacent normal tissues in these patients (*P* \< 0.001; Figure [4A](#F4){ref-type="fig"}), and the latter also differed in tumor tissues of the various serum AFP subgroups (*P* \< 0.001; Figure [4B](#F4){ref-type="fig"}). We also found a weak positive correlation between *PLCE1* and *AFP* mRNA expression in HBV-related HCC tumor tissues (r=0.107, *P*=0.019, Figure [4C](#F4){ref-type="fig"}). A gene interaction analysis by GeneMANIA predicted that *PLCE1* and *AFP* were involved in the *TP53* pathway (Figure [4D](#F4){ref-type="fig"}).

![**(A)** *AFP* and *PLCE1* mRNA expression in HBV-related HCC and adjacent normal tissue. **(B)** *AFP* mRNA expression level in HBV-related HCC tumor tissue from different serum AFP level subgroups. **(C)** Correlation between *PLCE1*and *AFP* gene expression levels. **(D)** Gene interaction networks between *PLCE1* and *AFP* genes.](oncotarget-08-29202-g004){#F4}

The samples were divided into two groups according to *PLCE1* mRNA expression in tumors. The high *PLCE1* group consisted of samples in which *PLCE1* mRNA expression levels were above the median value, with the remaining samples comprising the low *PLCE1* group. Since information on AFP levels were missing for four patients, 214 patients with serum AFP cut-off levels of 300 ng/ml were used for further joint-effects analysis. The results of the survival analysis for *PLCE1* and joint-effect analysis with AFP levels are shown in Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}, respectively. Patients with high *PLCE1* mRNA expression showed poor prognosis (adjusted HR = 1.668, 95%CI= 1.151--2.476, adjusted *P* = 0.007 for disease-free survival \[DFS\]; adjusted HR = 2.317, 95%CI= 1.448--3.706, adjusted *P* = 0.0005 for OS) (Figure [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}) as compared to those with low *PLCE1* mRNA expression. Patients with an AFP level \> 300 ng/ml had a shorter MST than those with AFP level ≤ 300 ng/ml (35 vs. 48 months, adjusted *P*=0.995), although the difference was not statistically significant. In the stratified analysis, high *PLCE1* expression increased the risk of recurrence and death among patients who were male and had early-stage BCLC, who had a single tumor, cirrhosis, AFP level \> 300 ng/ml (Figure [6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}). Old patients with high *PLCE1* expression also had a higher risk of recurrence Figure [6A](#F6){ref-type="fig"}). Meanwhile, high *PLCE1* expression among young patients with low AFP level and tumor size \> 5 cm had an increased risk of death (Figure [6B](#F6){ref-type="fig"}).

###### Survival analysis of PLCE1 mRNA expression and serum AFP levels in HBV-related HCC patients from GSE14520

  Variables          Patients (n=218)   DFS         OS                                                                        
  ------------------ ------------------ ----------- ---- --------------------- ------- ----------- ---- --------------------- --------
  **PLCE1 level**                                                                                                             
   **Low**           109                52 (47.7)   57   1                             31 (28.4)   NA   1                     
   **High**          109                69 (63.3)   29   1.688 (1.151-2.476)   0.007   53 (48.6)   53   2.317 (1.448-3.706)   0.0005
  **AFP (ng/ml)φ**                                                                                                            
   **≤300**          118                65 (55.1)   48   1                             40 (33.9)   56   1                     
   **\>300**         96                 55 (57.3)   35   1.001 (0.693-1.446)   0.995   43 (44.8)   49   1.234 (0.794-1.918)   0.351

Notes: φ Information of AFP was unavailable in 4 patients; § Adjustment for age, gender, cirrhosis, BCLC stage, serum AFP levels; DFS, disease-free survival; OS, overall survival; MST, median survival time; HR, hazard ratio; CI, confidence interval.

###### Joint-effects survival analysis of PLCE1 and serum AFP levels in HBV-related HCC patients from GSE14520

  Group       PLCE1 level   AFP (ng/ml)   Patients (n=214) φ   No. of events (%)   MST (months)   Adjusted HR(95% CI)   AdjustedP§
  ----------- ------------- ------------- -------------------- ------------------- -------------- --------------------- ------------
  **DFS**                                                                                                               
   **i**      **High**      **\>300**     47                   33 (70.2)           21             1                     
   **ii**     **High**      **≤300**      60                   36 (60.0)           41             0.777(0.476-1.266)    0.31
   **iii**    **Low**       **\>300**     49                   22 (44.9)           59             0.459(0.263-0.803)    0.006
   **iiii**   **Low**       **≤300**      58                   29 (50.0)           51             0.570(0.335-0.968)    0.038
  **OS**                                                                                                                
   **a**      **High**      **\>300**     47                   28 (59.6)           26             1                     
   **b**      **High**      **≤300**      60                   25 (41.7)           NA             0.709(0.404-1.246)    0.232
   **c**      **Low**       **\>300**     49                   15 (30.6)           NA             0.384(0.201-0.734)    0.004
   **d**      **Low**       **≤300**      58                   15 (25.9)           NA             0.347(0.180-0.670)    0.002

Notes: φ Information of AFP was unavailable in 4 patients; § Adjustment for age, gender, cirrhosis, BCLC stage, serum AFP levels; DFS, disease-free survival; OS, overall survival; MST, median survival time; HR, hazard ratio; CI, confidence interval.

![Kaplan-Meier survival curves of GSE14520 HBV-related HCC patient prognosis with different *PLCE1* mRNA expression levels, and joint-effects analysis with different serum AFP levels\
**(A, B)** DFS **(A)** and OS **(B)** stratified by *PLCE1* expression level. **(C, D)** DFS **(C)** and OS **(D)** stratified by joint-effects analysis of *PLCE1* expression and serum AFP levels.](oncotarget-08-29202-g005){#F5}

![Stratified analysis of the associations between *PLCE1* mRNA expression level and GSE14520 prognosis of HBV-related HCC patients\
Variables were stratified by favorable and adverse strata. **(A, B)** Stratified analysis between *PLCE1* and DFS **(A)** and between *PLCE1* and OS **(B)**.](oncotarget-08-29202-g006){#F6}

The joint-effects analysis of *PLCE1* mRNA expression and serum AFP levels showed that low *PLCE1* expression combined with any serum AFP level was associated with decreased risk of HBV-related HCC recurrence (adjusted HR = 0.459, 95%CI= 0.263--0.803, *P* = 0.006 for patients with low *PLCE1* expression and AFP level \> 300 ng/ml; adjusted HR = 0.570, 95%CI= 0.335--0.968, *P* = 0.038 for patients with low *PLCE1* expression and AFP level ≤ 300 ng/ml) (Figure [5C](#F5){ref-type="fig"}) and death (adjusted HR = 0.384, 95%CI= 0.201--0.734, adjusted *P* = 0.004 for patients with low *PLCE1* expression and AFP level \> 300 mg/ml; adjusted HR = 0.347, 95%CI= 0.180--0.670, adjusted *P* = 0.002 for patients with low *PLCE1* expression and AFP level ≤ 300 ng/ml) (Figure [5D](#F5){ref-type="fig"}) as compared to high *PLCE1* expression and AFP level \> 300 ng/ml.

DISCUSSION {#s3}
==========

PLCE1 is a member of phosphoinositide-specific PLC family that serves as a link between the second messengers and small GTPases and regulates some Ras family members \[[@R34], [@R35]\]. The *PLCE1* gene encodes a phospholipase that regulates various processes affecting cell growth, differentiation, and gene expression \[[@R36], [@R37]\] and was shown to promote intestinal tumorigenesis by inducing inflammation and angiogenesis in a transgenic mouse model \[[@R38]\].

The role of PLCE1 in human cancer remains controversial. It has been suggested to play a tumor suppressor role in and decrease the incidence of colorectal carcinoma (CRC) \[[@R39]--[@R41]\]. However, *PLCE1* is thought to act as an oncogene in bladder cancer \[[@R42], [@R43]\], non-small cell lung cancer \[[@R44]\], skin cancer \[[@R45]\], and head and neck cancer \[[@R46]\]. Upregulation of *PLCE1* mRNA level is associated with longer survival in gastric cardia adenocarcinoma (GCA) and ESCC, while the transcript is downregulated in GCA and ESCC tumor tissue \[[@R47]\], which was confirmed by another study of ESCC patients \[[@R30]\]. However, higher*PLCE1*expression was observed in Chinese Kazakh ESCC patients and ESCC tumor cell lines \[[@R48]\]. In an independent cohort, low PLCE1 expression were linked to poor prognosis in ESCC \[[@R47]\], contradicting a previous report \[[@R49]\]. Our analysis of HBV-related HCC cases from GSE14520 also showed that high *PLCE1* level predicts poor survival and increased risk of recurrence. Gene knockdown studies in ESCC cell lines suggested that *PLCE1* has an oncogenic function in ESCC \[[@R49], [@R50]\]. In addition, *PLCE1* expression was positively correlated with that of nuclear factor κB-related proteins in Kazakh ESCC patients \[[@R51]\], and negatively correlated with TP53 in HCC and ESCC cells and lung cancer \[[@R32], [@R52], [@R53]\]. Distinct microRNAs were shown to suppress *PLCE1* expression and thereby affect cancer development and patient prognosis \[[@R44], [@R49], [@R54]\].

Rs2274223 A\>G located in exon 26 of the *PLCE1* gene causes a missense mutation (His\>Arg) that alters gene expression \[[@R29]--[@R31]\]. Multiple case-control studies of Chinese patients revealed that thers2274223is a common susceptibility locus in several cancers, including gastric cancer(GC) \[[@R28], [@R55]--[@R58]\], CRC \[[@R59]--[@R62]\], ESCC \[[@R28], [@R30], [@R31], [@R37], [@R58], [@R63]--[@R69]\], and squamous cell carcinoma of the head and neck \[[@R46]\]. Other studies have reported similar findings for GC and ESCC in other ethnic groups \[[@R70]--[@R74]\], and even for gallbladder cancer in an Indian population \[[@R75], [@R76]\]. However, rs2274223 has not been linked to cancer risk in European CRC patients \[[@R77]\] or northern Indian ESCC patients \[[@R78]\]. Nonetheless, the results of recent meta-analyses indicate that the rs2274223 A \>G polymorphism is associated with increased susceptibility to cancer \[[@R27], [@R79]\]. A survival analysis based on 940 Chinese GC patients revealed that the G allele of rs2274223 was associated with a lower risk of death \[[@R80]\], but this was not true of other cancers. Our results indicate that the G allele of rs2274223 is a cancer risk factor. Rs3765524 C\>T also results in a missense mutation in an exon of *PLCE1*, and strong LD with rs2274223 has been reported in several studies \[[@R28], [@R31], [@R59], [@R78]\]. We also detected a strong LD(r^2^=1) between rs2274223 and rs3765524 in the CHB population and Chinese HBV-related HCC patients. A genome-wide association pathway analysis found that rs3765524 contributed to GC susceptibility \[[@R81], [@R82]\], while a case-control study of the Chinese population showed that rs3765524 was associated with disease risk in GC and ESCC \[[@R58], [@R67], [@R83]\]. Investigations of South Asian patients showed similar results for GC \[[@R72]\] but not for ESCC \[[@R78], [@R84]\]. Additionally, a recent meta-analysis showed that like rs2274223, rs3765524 was significantly associated with disease risk \[[@R79]\]. Given the many factors that can affect tumor incidence and the variable findings in different populations, additional studies are required to evaluate the significance of these polymorphisms in cancer \[[@R85]\].

The *PLCE1* haplotypes examined in the present study were not associated with OS in HBV-related HCC patients. Due to the limited sample size, survival analysis at three AFP cut-off levels showed no differences after adjustment in a COX proportional hazards regression model, contrary to the findings of a recent study \[[@R22]\]. Our results suggest that both the genotypes and haplotypes of rs2274223 and rs3765524 were significantly associated with HBV-related HCC incidence at AFP cut-off levels of 200 and 400 ng/ml. The GT haplotype had an increased risk of high AFP level in HBV-related HCC as compared to the AC haplotype. We also observed similar clinical outcomes in HCC patients grouped by haplotype and AFP cut-off levels of 200 and 400 ng/ml. In addition, according to an AFP cut-off level of 20 ng/ml, the distribution of *PLCE1* genotypes and haplotypes did not reach statistical significance in HBV-related HCC. However, a significant interaction between *PLCE1* haplotypes and a serum AFP cut-off level of 20 ng/ml was observed in a joint analysis. Grouping by *PLCE1* haplotype and an AFP cut-off level of 20 ng/ml, the outcomes of patients with AC or GT and AFP level ≥ 20 ng/ml differed from those with AC haplotypes and AFP level\< 20 ng/ml. These findings demonstrate that *PLCE1* gene polymorphisms combined with serum AFP level can serve as a prognostic marker for HBV-related HCC patients treated by hepatic resection. Once validated, *PLCE1* haplotypes of rs2274223 and rs3765524 may be used in combination with other clinical prognostic factors for decision-making in HCC management.

GEO data analysis of HBV-related HCC suggested that *PLCE1*mRNA expression was upregulated in tumor tissue, which predicted poor prognosis. These results imply that *PLCE1* acts as an oncogene in HBV-related HCC, and may be a potential therapeutic target. The stratified analysis also revealed that high *PLCE1* expression increased the risk of recurrence and death in patients who were male and had early-stage BCLC, a single tumor, cirrhosis, and AFP level \> 300 ng/ml. In addition, older patients had an increased risk of recurrence, whereas younger patients with low AFP level and tumor size \> 5 cm had a higher risk of death. These findings suggest that higher *PLCE1* expression was associated with tumor progression and degree of malignancy, which in turn affects clinical outcome. A recent report indicated that serum AFP is a valuable prognostic biomarker in HBV-related HCC and that lower preoperative serum AFP levels were associated with a much higher OS rate \[[@R22]\]. Our previous study of HBV-related HCC also demonstrated that serum AFP level was associated with 2-year OS and RFS, but was not useful for predicting long-term survival and recurrence in HBV-related HCC \[[@R86]\], which requires a combination of serum AFP and other markers. Indeed, in the present study the combination of serum AFP and *PLCE1* expression showed a strong interaction and better predictive value for HBV-related HCC prognosis.

In conclusion, *PLCE1* gene polymorphisms are associated with high AFP level(≥ 200 or 400ng/ml) in HBV-related HCC and can predict OS of patients following hepatic resection by stratification according to a serum AFP level of 20 ng/ml. In addition, we found that *PLCE1* mRNA expression combined with serum AFP stratified at 300 ng/ml can predict HBV-related HCC prognosis and recurrence. Thus, the *PLCE1* gene is a potential prognostic marker in HBV-related HCC, especially combined with serum AFP level. This is the first study reporting that the combination of serum AFP and *PLCE1* gene polymorphism and mRNA expression has significant predictive value for clinical outcome of HBV-related HCC patients. Our findings provide evidence for the value of *PLCE1*gene polymorphism and mRNA expression in distinguishing the morbidity and prognosis of different subgroups of HBV-related HCC, and provide a basis for the development of personalized treatment strategies.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University (approval no. 2015KY-E-032). Fresh surgically resected and pathologically confirmed HCC specimens (n = 421) collected at the First Affiliated Hospital of Guangxi Medical University from 2001 to 2013 were analyzed. All patients were positive for serum HBV surface antigen. Serum AFP levels were measured before hepatectomy. Cancer tissue specimens were collected during surgery and immediately stored at −80°C until use.

Genotyping {#s4_2}
----------

Genomic DNA was extracted from tumor samples using the TIANamp Genomic DNA kit (Tiangen Biotech, Beijing, China). Samples were genotyped by DNA sequencing with an ABIPrism 3100 system (Applied Biosystems/Shanghai Sangon Biological Engineering Technology and Services, Shanghai, China) using the following forward and reverse primers: 5′-GTTCTTGGGATTCCTTTGC-3′ and 5′-CA TGGGTGAGGCTGTACTTT-3′ for rs2274223; and 5′-GCTATGACTGTTTACTGGGATG-3′ and 5′-AAG GAGCGAGGTGAGCAT-3′ for rs3765524. Sequencing results were analyzed using Chromas software (<http://technelysium.com.au/wp/chromas/>) under conditions where signal-to-noise ratio was \> 98%.

Association analysis {#s4_3}
--------------------

Hardy-Weinberg equilibrium was estimated for each SNP with the goodness-of-fit χ^2^ test. Linkage disequilibrium (LD) between SNPs of the *PLCE1* gene was calculated using Haploview v.4.2, and the LD of normal CHB population was calculated based on published HapMap genotype data (<https://snpinfo.niehs.nih.gov/snpinfo/snptag.html>). Binary logistic regression was used to analyze the genetic model of *PLCE1* genotypes and haplotypes for different serum AFP levels and the association between clinical risk factors and *PLCE1* haplotypes. To investigate the association between *PLCE1* mRNA expression and serum AFP level in the prediction of HBV-related HCC patient survival, we analyzed the expression profile chip dataset of HBV-related HCC from GEO (GSE14520). GeneMANIA was used for gene interaction analysis.

Statistical analysis {#s4_4}
--------------------

The correlation between AFP level and *PLCE1* gene polymorphisms was assessed with the Spearman correlation coefficient. ORs and corresponding 95% CIs were calculated to estimate relative risk in the binary logistic regression model. Survival analysis was performed using the Kaplan-Meier method with the log-rank test for different clinical factors and haplotypes. Cox proportional hazards regression analysis was used to calculate the crude or adjusted HRs and 95% CIs in uni-and multivariate analyses, with adjustment for those with P \< 0.1 in the univariate analysis or selected variables. A *P* value \< 0.05 was considered statistically significant. Statistical analyses were carried out using SPSS v.20.0 software (IBM, Chicago, IL, USA).

SUPPLEMENTARY MATERIALS FIGURES {#s5}
===============================
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PLCE1

:   phospholipase C epsilon 1

AFP

:   α-fetoprotein

HBV

:   hepatitis B virus

HCC

:   hepatocellular carcinoma

SNPs
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OS

:   overall survival
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:   median survival time
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:   odds ratio
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